1.Therapeutic effect of ai-weizhi on anterior ischmic optic neuropathy
Lanhui WANG ; Jingwen WEI ; Zelong ZHONG
Chinese Journal of Ocular Fundus Diseases 1999;0(02):-
Objective To observe the therapeutic effect of ai-weizhi on anterior ischmic optic neuropathy (AION). Methods In 58 patients (60 eyes) who were diagnosed as with AION, 29 patients (30 eyes) underwent intravenous drip with ai-weizhi (1 200 mg/d) (treatment group), and the other 29 patients (30 eyes) underwent intravenous drip with 1-2 kinds of thrombolytic coagulant or vasodilator (once per day) (control group) with the period of treatment of 15 days. In the control group, ocular local injection, including gluco-corticosteroid and 654-2 behind or beside the eyeball injected once per day or every 2 days for 3-5 times, was perfomed on 20 eyes simultaneously. The changes of visual acuity and ocular fundus of the patients after injection were recorded, and the visual field was counterchecked in the patients who had underwent the examination before the treatment. Results The visual acuity was better in treatment group than which in control group with a significant difference (t=2.74, ?0.05). At the 5th、 10th and 15th day after treatment, the visual acuity was better in treatment group than which in control group with a significant difference(t=2.01, P
2.Pharmacokinetic analysis of raltitrexed using different ways of drug delivery
Qiaosheng HUANG ; Shaofeng CHEN ; Zelong ZHONG ; Weidong WANG ; Tao ZHANG ; Xiaoxia YU ; Guocheng LI ; Junyan WU ; Linfeng XU
Journal of Interventional Radiology 2018;27(2):157-162
Objective To study the pharmacokinetics of raltitrexed using different ways of drug delivery, including femoral venous infusion, hepatic artery perfusion, hepatic artery injection of lipiodol suspension, hepatic artery perfusion followed by embolization with Gelfoam. Methods According to the administration way of raltitrexed, a total of 40 New Zealand rabbit models with VX2 liver tumor were randomly divided into group A (femoral venous perfusion), group B (hepatic arterial perfusion), group C (hepatic artery injection of lipiodol suspension), and group D(hepatic artery perfusion followed by embolization with Gelfoam). Drug concentration in plasma were determined by using LC-MS/MS method and the pharmacokinetic parameters were calculated. Results After administration of raltitrexed, the Tmax was 5 minutes in all 4 groups. In group A, B, C and D, the values were (5.88±1.39), (7.31±2.60), (9.86±5.10) and (7.19±2.27) respectively, with group C having the longest t1/2 value, which was significantly different with that of group A (P<0.05); the (ng·ml-1·h-1) values were (2 056.40± 139.17), (1 389.21±180.28), (911.84±105.62) and (1 133.41±181.42)respectively, with the value of group A being obviously higher than that of group B, C and D (P<0.05) and the value of group C being the lowest; the AUC0-t(ng· ml-1·h-1) values were (5 482.72±1 007.07), (4 156.99±1 475.77), (2 785.13±1 107.36) and (3 903.64±947.25) respectively, with the value of group A being remarkably higher than that of group B, C and D (P<0.05) and the value of group C being the lowest. Conclusion Compared with the femoral vein infusion way, the ways of hepatic artery infusion, hepatic artery lipiodol suspension injection and hepatic artery perfusion followed by embolization with Gelfoam may promote more raltitrexed to deposit in the tumor area, thus, the curative effect is enhanced, the drug concentration in plasma is lowered and the side effects are alleviated.